• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Centre Hospitalier de Saint-Brieuc

    107论文总数
    904引用总数

    论文量&引用量时间轴

    机构学者

    论文(107)

    年份
    起
    –
    止
    排序
    1Hypofractionated Split-Course Versus Standard Radiotherapy in Frail Older Patients with Head and Neck Squamous-Cell Carcinoma (ELAN-RT Trial): a Non-Inferiority, Multicentre, Open-Label, Randomised Controlled Trial.
    Cécile Ortholan,Anne Aupérin,Yungan Tao, Sophie Renard,Yoann Pointreau, Cédrik Lafond,Guillaume Bera,Pierre Boisselier,Karen Benezery,Séverine Racadot,Florence Huguet, Marc Bollet,

    BACKGROUND:The standard treatment for older patients (aged ≥70 years) with localised, unresectable head and neck squamous-cell carcinoma is standard fractionated radiotherapy (SF-RT). However, its high toxicity and multiple fractions lead physicians to deliver tailored hypofractionated split-course radiotherapy (HSC-RT). The aim of the study was to compare these two radiotherapy methods in older patients. METHODS:This non-inferiority, multicentre, open-label, randomised controlled trial was done in 30 treating centres (cancer centres, university and general hospitals, and private clinics) across France and Monaco. Patients aged 70 years or older, assessed as frail by geriatric evaluation, with stage II-IV head and neck squamous-cell carcinoma and in curative intent were randomly assigned (1:1) to receive either SF-RT (70 Gy, 35 fractions over 7 weeks) or HSC-RT (55 Gy, 20 fractions, two courses of 2 weeks with 2 weeks stop). Randomisation was done by minimisation, and physicians and patients were not masked to the treatment group. The primary endpoint was the proportion of patients alive with complete locoregional response at 6 months, analysed in all randomly assigned patients (intention-to-treat population). The non-inferiority margin was set at 16%. The study was sponsored by the Groupe d'Oncologie Radiothérapie Tête et Cou (GORTEC) and is registered with ClinicalTrials.gov, NCT01864850. FINDINGS:Between Oct 21, 2013, and Aug 22, 2018, 102 patients were randomly assigned to the HSC-RT group and 100 patients to the SF-RT group. One patient in the HSC-RT group refused treatment and follow-up and so was excluded, resulting in 101 patients in the HSC-RT group. Median age was 82 years (IQR 77-86); 145 (72%) were male and 56 (28%) were female. Median follow-up for overall survival was 56·6 months (IQR 41-69). In the intent-to-treat population, 35 (35%) of 101 patients were alive with complete locoregional response at 6 months in the HSC-RT group versus 33 (33%) of 100 patients in the SF-RT group (difference +2%, 95% CI -11 to 15). In the per-protocol population, 35 (36%) of 97 patients were alive with complete locoregional response at 6 months in the HSC-RT group versus 33 (35%) of 95 patients in the SF-RT group (difference +1%, -12 to 15). Median overall survival was 13·0 months (95% CI 10·3 to 17·0) in the HSC-RT group versus 18·9 months (14·3 to 30·9) in the SF-RT group (hazard ratio 1·32, 95% CI 0·97 to 1·81). Eight patients died between radiotherapy start and 30 days after radiotherapy end (five [5%] in the HSC-RT group and three [3%] in the SF-RT group). One patient in the HSC-RT group had a grade 4 adverse event (kidney failure), as did four in the SF-RT group (two mucositis, one septic shock, and one hemiplegia). Acute adverse events grade 3-5 occurred in 33 (36%) of 91 patients in the HSC-RT group and in 44 (47%) of 93 patients in the SF-RT group (p=0·13; difference -11%, 95% CI -25 to 3). INTERPRETATION:Compared with SF-RT, HSC-RT did not decrease the 6-month complete locoregional response rate and could be an option for frail older patients. However, given the survival results, it should only be offered to patients deemed unsuitable for SF-RT after geriatric assessment. FUNDING:French programme PAIR-VADS 2011 (sponsored by the French National Cancer Institute, Fondation ARC, and Ligue Contre le Cancer), GEMLUC, and GEFLUC.

    2026The lancet Healthy longevity(2026)引用:2
    引用
    AI阅读
    加入学术空间
    2High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure
    Jean-Pierre Frat,Jean-Pierre Quenot,Christophe Guitton,Rémi Coudroy,Arnaud Gacouin,Julio Badie,Alexandre Demoule,Damien Contou,Guillaume Carteaux,Stephan Ehrmann, Fabien Jarousseau,Nicholas Sedillot,

    BACKGROUND:Data are needed on the effect of oxygen delivered through a high-flow nasal cannula, as compared with standard oxygen therapy, on intubation and mortality in patients with acute hypoxemic respiratory failure. METHODS:In this multicenter, open-label trial, we randomly assigned patients who had acute hypoxemic respiratory failure to receive high-flow-oxygen or standard-oxygen therapy. All the patients had a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 or less, a respiratory rate of more than 25 breaths per minute, and pulmonary infiltrate on chest imaging. The primary outcome was death by day 28. RESULTS:A total of 1116 patients underwent randomization. Of these patients, 1110 (556 in the high-flow-oxygen group and 554 in the standard-oxygen group) were included in the analysis. Mortality at day 28 was 14.6% (in 81 of 556 patients) in the high-flow-oxygen group and 14.6% (in 81 of 554 patients) in the standard-oxygen group (difference, -0.05 percentage points; 95% confidence interval [CI], -4.21 to 4.10; P = 0.98). The incidence of intubation by day 28 was 42.4% (in 236 of 556 patients) in the high-flow-oxygen group and 48.4% (in 268 of 554 patients) in the standard-oxygen group (difference, -5.93 percentage points; 95% CI, -11.78 to -0.08). Serious adverse events (cardiac arrest or pneumothorax) occurred during spontaneous breathing in 13 patients (2.3%) in the high-flow-oxygen group and in 6 patients (1.1%) in the standard-oxygen group. CONCLUSIONS:Among patients with acute hypoxemic respiratory failure, the use of oxygen delivered through a high-flow nasal cannula did not significantly reduce mortality at day 28. (Funded by the French Ministry of Health and Fisher and Paykel Healthcare; SOHO ClinicalTrials.gov number, NCT04468126.).

    2026The New England journal of medicine(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Angiography-derived Fractional Flow Reserve- Vs Usual Care-Guided Percutaneous Coronary Intervention: Interim Analysis of the PIONEER IV Trial.
    Patrick W Serruys, Tsung-Ying Tsai, Joanna J Wykrzykowska,Faisal Sharif,Liesbeth Rosseel,Mohammad Alkhalil,Nick Curzen,Vincent Floré,Edouard Benit,Yoann Bataille,Mathieu Pankert,Clemens von Birgelen,
    2026European heart journal(2026)
    引用
    AI阅读
    加入学术空间
    4Invasive Meningococcal Disease in Adults Aged ≥65 Years Admitted to French Intensive Care Units: A Nationwide Comparison with Younger Adults.
    Damien Contou, Benoit Painvin, Delphine Daubin,Arthur Orieux, Hugo Pirollet,Martin Cour, Benjamin Sarton,Marie Gauvrit,Mathilde Taillantou-Candau, Paola Lepoutre,Guillaume Louis,Fabrice Bruneel,

    BACKGROUND:Invasive meningococcal disease (IMD) is traditionally associated with younger populations, but its impact on older adults is rising. We aimed to describe the clinical characteristics and outcomes of critically ill older patients with IMD and identify risk factors for in-hospital mortality. METHODS:We conducted an ancillary analysis of the French nationwide multicenter RETRO-MENINGO cohort (2016-2024). All adults admitted to 102 ICUs with microbiologically confirmed IMD were included and stratified by age (≥65 vs. <65 years). The primary outcome was all-cause in-hospital mortality. Multivariable logistic regression identified factors independently associated with death. RESULTS:Among 654 patients, 114 (17%) were aged ≥65 years, of whom only 0.9% were reported as vaccinated. Compared to younger adults, older patients presented more frequently with hemodynamic failure and less often with classic purpura or meningeal symptoms. Serogroup W predominated in the older group, while serogroup B was more common in younger patients. Older adults required more organ support and had significantly higher in-hospital mortality (28.1%, n=32/114 vs. 9.6%, n=52/540 p<0.001). After adjustment, age ≥65 years remained independently associated with in-hospital mortality (aOR 2.99; 95% CI 1.57-5.72; p<0.001), while administration of a third-generation cephalosporin before ICU admission was protective (aOR 0.45; 95% CI, 0.24-0.84; p=0.01). CONCLUSIONS:Critically ill older adults with IMD exhibit atypical clinical features, a high prevalence of serogroup W, and nearly triple the in-hospital mortality of younger patients. These findings emphasize the need for high clinical suspicion, rapid antibiotic therapy, and potential expansion of vaccination strategies to include older populations.

    2026Clinical infectious diseases an official publication of the Infectious Diseases Society of America(2026)
    引用
    AI阅读
    加入学术空间
    5Renal Replacement Therapy in an Intensive Care Unit: Guidelines from the SRLF-GFRUP Consensus Conference.
    Mercè Jourdain, Ines Gragueb Chatti, Brahim Housni,Pierre Jaquet, Mélissa Jezequel, Oumar Kane, Béatrice La Combe, Mickael Landais, Mehdi Marzouk,Etienne de Montmollin,Guillaume Mortamet, Mai-Anh Nay,

    BACKGROUND:Although largely used, the place of extracorporeal renal replacement therapy (RRT) in acute kidney injury (AKI) in intensive care unit (ICU) patients has yet to be clarified. The French Intensive Care Society (Société de Réanimation de Langue Française, SRLF) and the French Pediatric Group of Intensive Care and Emergency (Groupe Francophone de Réanimation et d'Urgence Pédiatrique, GFRUP) organized a consensus conference in November 2024. METHODS:A committee, without any conflict of interest (CoI) on the subject, defined seven generic questions and drew up a list of sub questions according to the population, intervention, comparison and outcomes (PICO) model. An independent work group reviewed literature using predefined keywords. The quality of the data was assessed using the GRADE methodology. Eighteen experts in the field from both societies proposed their own answers in a public session and answered questions from the jury (a panel of 14 critical-care medicine physicians and a nurse) and the public. The jury then met for 48 h to write out and vote on its recommendations. RESULTS:The panel provided 45 statements addressing seven questions. In patients, adults or children, admitted to the ICU with AKI (1) What are the indications for RRT, when should it be initiated, and within what timeframe? (2) What are the advantages/disadvantages of the different RRT modalities in ICU, and based on what criteria should they be chosen? (3) Which dose of dialysis should be prescribed for ICU patients? (4) How to prescribe, adjust and monitor each RRT technique? (5) Which vascular access technique should be preferred (insertion site, catheter type and length)? (6) How to prevent circuit thrombosis? (7) What are the criteria to consider weaning from RRT and how can it be achieved? CONCLUSIONS:These recommendations should optimize the prescription and use of RRT during AKI in ICUs for both adult and pediatric patients.

    2025Annals of Intensive Care(2025)引用:9
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 107 篇论文

    合作机构(100)

    巴黎医院公共援助合作论文 14
    Centre Hospitalier Universitaire de Rennes合作论文 12
    Centre Hospitalier de Saint-Malo合作论文 8
    里昂市民临终关怀院合作论文 7
    Centre Hospitalier de Cornouaille合作论文 6
    Hôpital Intercommunal de Créteil合作论文 6
    Institut Supérieur de l''Électronique et du Numérique合作论文 6
    Centre Hospitalier de Bretagne Sud合作论文 6
    Centre Hospitalier Universitaire de Bordeaux合作论文 5
    莱昂·贝拉德中心合作论文 5

    机构统计